A drug–drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors.
N. Agarwal
No relevant relationships to disclose
M. Sahu
Consultant or Advisory Role - Vanthys
D. J. Abhyankar
Consultant or Advisory Role - Vanthys
T. L. Werner
No relevant relationships to disclose
B. Benjamin
Consultant or Advisory Role - Vanthys
N. R. Srinivas
Consultant or Advisory Role - Vanthys
S. Sharma
No relevant relationships to disclose